Navigating Process Development and Scale Up Challenges with Antibody-Drug Conjugates
Thursday, October 10, 2024
Antibody-Drug Conjugates (ADCs) are reaching a crescendo of interest from around the industry, with an increasing number of assets seen progressing rapidly through clinical stages. With this comes the pressing need to optimize all processes associated with their manufacture, whether this is conjugation, purification, scalability, or anything else. Join Merck, Amgen, Zymeworks, and our partner Cytiva, as we hear from some of the leading experts in cutting-edge companies in the space. They'll share their process development strategies to convert all the excitement into tangible ADC success!
Attend this webinar to learn:
- Approaches to scale up supply for early clinical studies
- Advantages and disadvantages to integrated supply chains
- Tech transfer strategies from developer to CDMO
- Harmonising stakeholder needs across CMC, PD and manufacturing
Speakers & Panelists
Xiaolin Zhang
Associate Principal Scientist
Seb Caille
Scientific Director
Geoff Winters
Director
Cytiva and Pall Life Sciences have come together to deliver the breadth, depth, and scale researchers and biopharma need to advance future therapeutics—from discovery to delivery. Together, as Cytiva, we supply the tools and support our customers need to work better, faster, and safer, leading to the delivery of transformative medicines to patients. Our combined portfolio includes well-recognized names such as Allegro™, Supor™, iCELLis™, and Kleenpak™, in addition to ÄKTA™, Amersham™, Biacore™, FlexFactory™, HyClone™, MabSelect™, Sefia™, Whatman™, and Xcellerex™.
Visit cytiva.com to learn more.